These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 35832459)

  • 1. A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world.
    Shi Y; Ji M; Jiang Y; Yin R; Wang Z; Li H; Wang S; He K; Ma Y; Wang Z; Lu J; Shi M; Shen B; Zhou G; Leong TL; Wang X; Chen C; Feng J
    Transl Lung Cancer Res; 2022 Jun; 11(6):1051-1068. PubMed ID: 35832459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
    Chen Q; Li Y; Zhang W; Wang C; Yang S; Guo Q
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):401-408. PubMed ID: 34797416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of immune checkpoint inhibitors combined with chemotherapy or anti-angiogenic therapy as a second-line or later treatment option for advanced non-small cell lung cancer: a retrospective comparative cohort study.
    Chen B; Wang J; Pu X; Li J; Wang Q; Liu L; Xu Y; Xu L; Kong Y; Li K; Xu F; Liang S; Cardona AF; Wu L
    Transl Lung Cancer Res; 2022 Oct; 11(10):2111-2124. PubMed ID: 36386462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of anlotinib with and without EGFR-TKIs or immunotherapy in the treatment of elder patients with non-small-cell lung cancer: a retrospective study.
    Wang W; Shao L; Xu Y; Song Z; Lou G; Zhang Y; Chen M
    BMC Pulm Med; 2022 May; 22(1):179. PubMed ID: 35524294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of anlotinib in combination with immune checkpoint inhibitors or not as advanced non-small cell lung cancer treatment: a systematic review and network meta-analysis.
    Wu Z; Zhou P; Zhao Y; Wang J; Gao S
    Transl Cancer Res; 2024 May; 13(5):2451-2463. PubMed ID: 38881944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy and safety of anlotinib monotherapy or anlotinib plus immune checkpoint inhibitor for advanced small cell lung cancer with brain metastases.
    Xu M; Shao K; Wang Y; Hao Y; Song Z
    Clin Transl Oncol; 2024 Jul; 26(7):1687-1695. PubMed ID: 38363527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy and safety of immune checkpoint inhibitors plus anlotinib as secondline or subsequent therapy in extensive stage small cell lung cancer: a retrospective study.
    Wu Y; Zhang Y; Tian Y; Lv Y; Zhang J
    Clin Transl Oncol; 2024 Aug; ():. PubMed ID: 39115676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study.
    Zhong Q; Liu Z
    Cancer Manag Res; 2021; 13():4115-4128. PubMed ID: 34045898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy strategies for EGFR-mutated advanced NSCLC after EGFR tyrosine-kinase inhibitors failure.
    Li X; Huang H; Sun Y; Jiang Q; Yu Y
    Front Oncol; 2023; 13():1265236. PubMed ID: 37869096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy and safety of multitarget angiogenesis inhibitor combined with immune checkpoint inhibitor and nivolumab monotherapy as second-line or beyond for advanced lung adenocarcinoma in driver-negative patients: a retrospective comparative cohort study.
    Yu L; Xu J; Qiao R; Zhong H; Brueckl WM; Zhong R
    Transl Lung Cancer Res; 2023 May; 12(5):1108-1121. PubMed ID: 37323173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of first-line anlotinib-based combinations for advanced non-small cell lung cancer: a three-armed prospective study.
    Chu T; Zhang W; Zhang B; Zhong R; Zhang X; Gu A; Shi C; Wang H; Xiong L; Lu J; Qian J; Zhang Y; Dong Y; Teng J; Gao Z; Wang W; Shen Y; Nie W; Lim JU; Mehta HJ; Neal JW; Lou Y; Xu J; Zhong H; Han B
    Transl Lung Cancer Res; 2022 Jul; 11(7):1394-1404. PubMed ID: 35958322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Anlotinib-Containing Regimens in Advanced Non-Small Cell Lung Cancer: A Real-World Study.
    Sun L; Zhao Q; Wang Y; Wang Y; Zheng M; Ding X; Miao L
    Int J Gen Med; 2023; 16():4165-4179. PubMed ID: 37720175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for non-small cell lung cancer with EGFR or HER2 exon 20 insertion mutations: a real-world analysis.
    Zhang M; Huang Q; Yu M; Xue J; Huang M; Lu Y; Zhang Y
    Transl Lung Cancer Res; 2023 Apr; 12(4):797-807. PubMed ID: 37197626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety analysis of immune checkpoint inhibitor rechallenge therapy in locally advanced and advanced non-small cell lung cancer: a retrospective study.
    Yan X; Zhao L; Wu F; Shen B; Zhou G; Feng J; Yue C; Zhu J; Yu S
    J Thorac Dis; 2024 Mar; 16(3):1787-1803. PubMed ID: 38617775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
    Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C
    Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitors alone or in combination with chemotherapy for treatment of advanced non-small cell lung cancer after first-line platinum-based chemotherapy: A propensity score matching analysis.
    Qiu L; Gao S; Du S; Sun S; Liang Y; Sun Z; Li T; Jia G; Li K; Sun X; Jiao S; Zhao X
    Front Oncol; 2022; 12():974227. PubMed ID: 36523994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study.
    Zheng HR; Jiang AM; Gao H; Liu N; Zheng XQ; Fu X; Zhang R; Ruan ZP; Tian T; Liang X; Yao Y
    Cancer Manag Res; 2022; 14():2273-2287. PubMed ID: 35942069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study.
    Tian T; Yu M; Yu Y; Wang K; Tian P; Luo Z; Ding Z; Wang Y; Gong Y; Zhu J; Zou B; Sio TT; Alves A; Liu Y; Huang M; Lu Y
    Transl Lung Cancer Res; 2022 Jun; 11(6):1027-1037. PubMed ID: 35832458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation.
    Tian T; Yu M; Li J; Jiang M; Ma D; Tang S; Lin Z; Chen L; Gong Y; Zhu J; Zhou Q; Huang M; Lu Y
    Front Oncol; 2021; 11():739090. PubMed ID: 34888234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non-Small Cell Lung Cancer.
    Xiong Q; Qin B; Xin L; Yang B; Song Q; Wang Y; Zhang S; Hu Y
    Front Oncol; 2021; 11():659380. PubMed ID: 34395243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.